Loading...

Donna Peehl, PhD

TitleAdjunct Professor
SchoolUCSF School of Medicine
DepartmentRadiology
Address1700 4th St
San Francisco CA 94158
Phone650-725-5531
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco Postdoctoral FellowOncogenes
    University of California, Irvine Postdoctoral FellowTumor Suppressors
    University of Colorado, Boulder Doctor of PhilosophyMolecular, Cellular and Developmental Biology
    Stanford University, California UndergraduateBiology
    Collapse Awards and Honors
    SWIU/SBUR 2016Award for Excellence in Urologic Research

    Collapse Overview 
    Collapse Overview
    Donna Peehl, PhD, is an adjunct Professor in the Body Research Interest Group in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. She received her undergraduate degree in biology at Stanford University in California and completed her PhD in Molecular, Cellular and Developmental Biology at the University of Colorado in Boulder. During postdoctoral fellowship research at the University of California in Irvine and San Francisco, she investigated tumor suppressor genes and oncogenes in cancer. Prior to joining UCSF, Dr. Peehl became Professor Emerita at Stanford University, California, after 35 years as a basic scientist in the Department of Urology. She is widely recognized for her work in developing realistic and representative preclinical cell and tissue models of prostate and kidney cancer.

    Dr. Peehl’s current studies focus on developing novel therapeutics for prostate and kidney cancer. In collaboration with investigators at UCSF and Stanford, she is testing novel inhibitors of the tyrosine kinase AXL and of the scaffold protein, IQGAP, for their anti-cancer activity in her patient-derived models of kidney cancer. Another project uses tissue slice cultures to investigate cancer-associated glycosylation as a novel immunotherapy target. Under the auspices of a new NIH U01 grant, Dr. Peehl is collaborating with Dr. John Kurhanewicz and others at UCSF to compare metabolism of four types of kidney cancer preclinical models by hyperpolarized molecular imaging.

    Dr. Peehl has been the recipient of numerous grants from the NIH and Department of Defense (DoD) Prostate Cancer Research Program, and has received awards from the Prostate Cancer Foundation (formerly CaP CURE) to support her research. She has served as chair or scientist reviewer for many NIH and grant review panels and has reviewed or served on the editorial board for a large number of scientific journals. Her peer-reviews include over 200 articles and publications.

    Expertise:
    Urology

    Specialty:
    Prostate cancer, kidney cancer, molecular and cellular biology

    Professional Interests:
    Patient-derived xenografts, tissue slice cultures, primary cultures, spheroid cultures, preclinical drug testing, biomarkers, metabolism, cancer biology, translational science


    Collapse Research 
    Collapse Research Activities and Funding
    Metabolic imaging comparisons of patient-derived models of renal cell carcinoma
    NIH/NCI U01CA217456Sep 1, 2017 - Jul 31, 2022
    Role: Co-Principal Investigator
    A Serum Marker for Aggressive Prostate Cancer
    NIH/NCI R01CA121460Aug 28, 2006 - Jul 31, 2013
    Role: Principal Investigator
    GROWTH FACTORS IN THE PROSTATE: AN IN VITRO MODEL
    NIH/NIDDK R01DK047551Sep 30, 1993 - Aug 31, 1996
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sriram R, Van Criekinge M, DeLos Santos J, Keshari KR, Wilson DM, Peehl D, Kurhanewicz J, Wang ZJ. Non-invasive differentiation of benign renal tumors from clear cell renal cell carcinomas using clinically translatable hyperpolarized 13C pyruvate magnetic resonance. Tomography. 2016 Mar; 2(1):35-42. PMID: 27227168.
      View in: PubMed
    2. Keshari KR, Wilson DM, Van Criekinge M, Sriram R, Koelsch BL, Wang ZJ, VanBrocklin HF, Peehl D, O'Brien T, Sampath D, Carano RA, Kurhanewicz J. Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor. Prostate. 2015 Oct; 75(14):1601-9. PMID: 26177608; PMCID: PMC4537380 [Available on 10/01/16].
    3. Cerchiari AE, Garbe JC, Jee NY, Todhunter ME, Broaders KE, Peehl D, Desai TA, LaBarge MA, Thomson M, Gartner ZJ. A strategy for tissue self-organization that is robust to cellular heterogeneity and plasticity. Proc Natl Acad Sci U S A. 2015 Feb 17; 112(7):2287-92. PMID: 25633040; PMCID: PMC4343104.
    4. Valta MP, Zhao H, Ingels A, Thong AE, Nolley R, Saar M, Peehl D. Development of a realistic in vivo bone metastasis model of human renal cell carcinoma. Clin Exp Metastasis. 2014 Jun; 31(5):573-84. PMID: 24715498; PMCID: PMC4351963.
    5. Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl D. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer. 2014 May 15; 134(10):2322-9. PMID: 24243565; PMCID: PMC4365782.
    6. Zhao H, Thong A, Nolley R, Reese SW, Santos J, Ingels A, Peehl D. Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy. J Transl Med. 2013 Aug 28; 11:199. PMID: 23985008; PMCID: PMC3766103.
    7. Thong AE, Zhao H, Ingels A, Valta MP, Nolley R, Santos J, Young SR, Peehl D. Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential. Urol Oncol. 2014 Jan; 32(1):43.e23-30. PMID: 23911681; PMCID: PMC4350678.
    8. Keshari KR, Sriram R, Van Criekinge M, Wilson DM, Wang ZJ, Vigneron DB, Peehl D, Kurhanewicz J. Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate. 2013 Aug; 73(11):1171-81. PMID: 23532911; PMCID: PMC3976546.
    9. Hughes AJ, Lin RK, Peehl D, Herr AE. Microfluidic integration for automated targeted proteomic assays. Proc Natl Acad Sci U S A. 2012 Apr 17; 109(16):5972-7. PMID: 22474344; PMCID: PMC3341062.
    10. Levin YS, Albers MJ, Butler TN, Spielman D, Peehl D, Kurhanewicz J. Methods for metabolic evaluation of prostate cancer cells using proton and (13)C HR-MAS spectroscopy and [3-(13)C] pyruvate as a metabolic substrate. Magn Reson Med. 2009 Nov; 62(5):1091-8. PMID: 19780158; PMCID: PMC2783184.
    11. Kim J, Choi YL, Vallentin A, Hunrichs BS, Hellerstein MK, Peehl D, Mochly-Rosen D. Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res. 2008 Aug 15; 68(16):6831-9. PMID: 18701509; PMCID: PMC2597632.
    12. Vidanes GM, Paton V, Wallen E, Peehl D, Navone N, Brooks JD. Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate. 2002 Jun 1; 51(4):225-30. PMID: 11987150.
      View in: PubMed
    13. Carroll PR, Fair WR, Grossfeld GD, Heston WD, Lieberman R, Malkowicz SB, Stricker HJ, Sylvester J, Peehl D, Meyer F, Hart C. Overview consensus statement. Urology. 2001 Aug; 58(2 Suppl 1):1-4. PMID: 11502434.
      View in: PubMed
    14. Lee KO, Oh Y, Giudice LC, Cohen P, Peehl D, Rosenfeld RG. Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: a comparison of normal and vasectomized patients. J Clin Endocrinol Metab. 1994 Nov; 79(5):1367-72. PMID: 7525634.
      View in: PubMed
    15. Pastan I, Lovelace E, Rutherford AV, Kunwar S, Willingham MC, Peehl D. PR1--a monoclonal antibody that reacts with an antigen on the surface of normal and malignant prostate cells. J Natl Cancer Inst. 1993 Jul 21; 85(14):1149-54. PMID: 7686582.
      View in: PubMed
    16. Cohen P, Graves HC, Peehl D, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 1992 Oct; 75(4):1046-53. PMID: 1383255.
      View in: PubMed
    Donna's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP